Business Wire

Saudi Telecom Company Embarks on Extensive 5G Expansion with Juniper Networks Core Network Solutions, Revolutionizing User Experience, Transforming Digital Connectivity Access and Modernizing its Data Centers Throughout Saudi Arabia

Share

Juniper Networks supports stc to achieve extraordinary core network milestones, leading to an 864-port boost in 400G capacity per rack space and reducing power consumption by 43 percent

Juniper Networks, (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced that Saudi Telecom Company (stc), the largest telecoms operator in the Kingdom of Saudi Arabia, is expanding its 5G services to reach a total of 75 cities and regions. By leveraging Juniper 400G routers in its Converged Supercore network and key data centers, stc can dramatically improve network capacity, performance and scale, while reducing energy use, all fully aligned with its ongoing digital transformation agenda. Additionally, incorporating automation into the infrastructure further streamlines operations and optimizes efficiency, ensuring a seamless user experience.

stc Advances digital transformation with modernized Data center and core network

As stc planned its 5G services expansion, it needed to increase the capacity of the core network and key data centers powering its business and operational support systems for mobile, broadband, residential and B2B services. The objective was to create an elastic fabric with proven performance, able to streamline operations and simplify the network as services grow and evolve. stc prioritized the adoption of energy-efficient technology, underlining its commitment to environmental sustainability, deploying a 400G routing solution that can meet its optimized power and space requirements in support of its goals.

Supercore network convergence driven by PTX10008 Routers

stc uses Juniper Networks® PTX10008 Packet Transport Routersto transform its Converged Supercore network. The PTX10008 router delivers 115.2 Tbps capacity within a compact 13-U footprint and is 800G-ready to meet future demands. The core upgrade results in a remarkable 1,340 percent (14.4 times) increase in 100G capacity and an 864-port boost in 400G capacity per rack space, with a 43 percent reduction in watts/gig power consumption through ground-breaking silicon innovation.

Data Center modernization driven by MX10008 Routers

stc's modernized data center, powered by MX10008 routers, delivers a capacity of 76.8 Tbps within a 13 RU form factor and is ready for 400G adoption. This modernization effort enabled byJuniper Networks® MX Series Universal Routersdelivers a 384-port boost in 400G capacity per site, whilst also achieving a 90 percent reduction in the physical space requirements per site and an 87 percent decrease in watts/gig power consumptioncompared to previous multi-layer designs.

Model-driven automation

By integrating Juniper's highly programmable PTX and MX platforms, stc can accelerate model-driven automation to streamline operations. These platforms are equipped with gRPC services, OpenConfig, NETCONF/Yang and native data models, demonstrating the solutions' simplicity and flexibility.

Supporting Quotes:

“stc already offers the fastest mobile experiences in Saudi Arabia. This expansion allows us to bring transformative 5G services to millions more people and businesses. With Juniper routing at the heart of our core network and key operational data centers, stc can continue to attract and retain mobile customers at scale while also reducing our carbon footprint and operational expenditure.

We are also excited about the promise of Juniper’s 800GE PTX routers that embody sustainability and versatility, delivering superior performance and seamless user experience, reduced carbon footprint and operational cost advantages.”
- Bader Allhieb, Infrastructure VP, stc

“Greater access to 5G is crucial for accelerating Saudi Arabia’s rapid digital transformation as it works towards Vision 2030 and beyond, while also supporting the growth of enterprises across the country. Juniper Networks provides stc with the solid foundation to transform its services and significantly advance end-user experiences.”
Yarob Sakhnini, Sales VP META, Juniper Networks

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver exceptional, highly secure and sustainable user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250303036885/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release

- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release

-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release

Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye